Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia

Drug and Alcohol Dependence

Volumn 111, Issue 1-2, 2010, Pages 44-49

  Vicknasingam, B ^a   Mazlan, M ^b   Schottenfeld, R S ^c   Chawarski, M C ^c  

^a SCHOOL OF PHYSICS   (Malaysia)

^b Substance Abuse Center   (Malaysia)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Buprenorphine naloxone; HIV and infectious disease risk factors; Injection drug use; Malaysia

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE;

ADULT; ARTICLE; DRUG ABUSE PATTERN; DRUG DEPENDENCE; DRUG MISUSE; DRUG PREFERENCE; DYSPNEA; FATIGUE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE INFECTION; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MUSCLE FATIGUE; PATIENT ATTITUDE; PRIORITY JOURNAL; SELF REPORT; SIDE EFFECT; TABLET; THORAX PAIN; WEIGHT REDUCTION;

ADULT; BUPRENORPHINE; FEMALE; HEALTH BEHAVIOR; HEALTH SURVEYS; HEROIN; HUMANS; INJECTIONS, INTRAVENOUS; MALAYSIA; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NEEDLE SHARING; OPIOID-RELATED DISORDERS; PATIENT SELECTION; PREVALENCE; RISK MANAGEMENT; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 77956181343     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.03.014     Document Type: Article

References (29)

1. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007, 88:75-78.
2. Bruce R.D., Govindasamy S., Sylla S., Haddad M.S., Kamarulzaman A., Altice F. Case series of buprenorphine injectors in Kuala Lumpur, Malaysia. Am. J. Drug Alcohol Abuse 2008, 34:511-517.
3. Bruce R.D., Govindasamy S., Sylla L., Kamarulzaman A., Altice F. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am. J. Drug Alcohol Abuse 2009, 35:68-72.
4. Cicero T.J., Surratt H., Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J. Opioid Manage. 2007, 3:1-7.
5. Chawarski M.C., Pakes J., Schottenfeld R.S. Assessment of HIV risk. J. Addict. Dis. 1998, 17:49-59.
6. Chua S.-M., Lee T.-S. Abuse and prescription buprenorphine, regulatory controls. Ann. Acad. Med. 2006, 35:492-495.
7. Comer S.D., Collins E.D. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J. Pharmacol. Exp. Ther. 2002, 70:S29-S37.
8. Institute of Medicine Preventing HIV Infection among Injecting Drug Users in High Risk Countries: An Assessment of the Evidence 2006, The National Academies Press, Washington, DC.
9. Jenkinson R.A., Clark N.C., Fry C.L., Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?. Addiction 2005, 100:197-205.
10. Hakansson A., Medvedeo A., Andersson M., Berglund M. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration. Eur. Addict. Res. 2007, 13:207-215.
11. Harris D.S., Jones R.T., Welm S., Upton R.A., Lin E., Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 2000, 61:85-94.
12. Lee C.E. Tackling subutex abuse in Singapore. Singapore Med. J. 2006, 47:919.
13. Mammen K., Bell J. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin. Pharmacother. 2009, 10:2537-2544.
14. Mandelson J., Jones R.T. Clinical and pharmacological evaluations of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment. Drug Alcohol Depend. 2003, 70:S29-37.
15. Mazlan M., Vicknasingam B., Chawarski M.C., Schottenfeld R.S. Characteristics of opiate IDUs with and without ATS abuse in Kuala Lumpur, Malaysia. College on the Problems of Drug Dependence 71st Annual Scientific Meeting 2009.
16. Narcotics Bulletin Ministry of Internal Security and Home Affairs Malaysia 2007.
17. National Anti Drug Agency, National Drug Information System Ministry of Internal Security and Home Affairs Malaysia January 2007.
18. Nielsen S., Dietze P., Lee N., Dunlop A., Taylor D. Concurrent buprenorphine and benzodiazepine use and self-reported opioid toxicity substitution treatment. Addiction 2007, 102:616-622.
19. Nigam A.K., Srivastava R.P., Saxena S., Chavan B.S., Sundaram K.R. Naloxone-induced withdrawal in patients with buprenorphine dependence. Addiction 1994, 89:317-320.
20. Obadia Y., Perrin V., Feroni I., Vlahov D., Moatti J.P. Injecting misuse of buprenorphine among French drug users. Addiction 2001, 96:267-272.
21. Robinson G.M., Dukes P.D., Robinson B.J., Cooke R.R., Mahoney G.N. The misuse of buprenorphine and buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend. 1993, 33:81-86.
22. Schottenfeld R.S., Chawarski M.C., Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:2192-2200.
23. Singh R.A., Mattoo S.K., Malhotra A., Varma V.K. Cases of buprenorphine abuse in India. Acta Psychiat. Scand. 1992, 86:46-48.
24. Strang J. Abuse of buprenorphine. Lancet 1985, 28:725.
25. The Star Tougher Penalties for Errant Clinics November 2006.
26. Vicknasingam B., Navaratnam V. The use of rapid assessment methodology to compliment existing national assessment and surveillance data: a study among injecting drug users in, Penang, Malaysia. Int. J. Drug Policy 2008, 90-93.
27. Vicknasingam B., Mazlan M., Chawraski M.C., Schottenfeld R.S. Malaysia's evolving response to heroin dependence, injection drug use and HIV/AIDS-initial experience with buprenorphine maintenance treatment. NIDA International Forum 2007.
28. Vidal-Trecan G., Varescon I., Nabet N., Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 2003, 69:175-181.
29. Villiger J.W., Taylor K.M. Buprenorphine high-affinity binding to dorsal spinal cord. J. Neurochem. 1982, 38:1771-1773.